Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT...
Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial
About this item
Full title
Author / Creator
SIOP Renal Tumours Study Group , Faculty of Medicine , Medicinska fakulteten , Division of Clinical Genetics , Department of Laboratory Medicine , Avdelningen för klinisk genetik , Pathways of cancer cell evolution , Institutionen för kliniska vetenskaper, Lund , Lunds universitet , Department of Clinical Sciences, Lund , Childhood Cancer Research Unit , Paediatrics (Lund) , Lund University , Institutionen för laboratoriemedicin , Sektion V , Pediatrik, Lund , Section V , Cancercellers evolution , Pritchard-Jones, Kathy, Prof , Bergeron, Christophe, MD , de Camargo, Beatriz, MD , van den Heuvel-Eibrink, Marry M, MD , Acha, Tomas, MD , Godzinski, Jan, MD , Oldenburger, Foppe, MD , Boccon-Gibod, Liliane, MD , Leuschner, Ivo, Prof , Vujanic, Gordan, Prof , Sandstedt, Bengt, MD , de Kraker, Jan, MD , van Tinteren, Harm, PhD and Graf, Norbert, MD
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Before this study started, the standard postoperative chemotherapy regimen for stage II–III Wilms' tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related cardiotoxicity effects is important to improve long-term outcomes for childhood cancers that have excellent prognosis. We aime...
Alternative Titles
Full title
Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial
Authors, Artists and Contributors
Author / Creator
Faculty of Medicine
Medicinska fakulteten
Division of Clinical Genetics
Department of Laboratory Medicine
Avdelningen för klinisk genetik
Pathways of cancer cell evolution
Institutionen för kliniska vetenskaper, Lund
Lunds universitet
Department of Clinical Sciences, Lund
Childhood Cancer Research Unit
Paediatrics (Lund)
Lund University
Institutionen för laboratoriemedicin
Sektion V
Pediatrik, Lund
Section V
Cancercellers evolution
Pritchard-Jones, Kathy, Prof
Bergeron, Christophe, MD
de Camargo, Beatriz, MD
van den Heuvel-Eibrink, Marry M, MD
Acha, Tomas, MD
Godzinski, Jan, MD
Oldenburger, Foppe, MD
Boccon-Gibod, Liliane, MD
Leuschner, Ivo, Prof
Vujanic, Gordan, Prof
Sandstedt, Bengt, MD
de Kraker, Jan, MD
van Tinteren, Harm, PhD
Graf, Norbert, MD
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_512117
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_512117
Other Identifiers
ISSN
0140-6736,1474-547X
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(14)62395-3
How to access this item
ERROR: Invalid URL specified.
